MedTrace Logo

A Phase II Study of BI-505 in Smoldering Multiple Myeloma

NCT01838369 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2023-01-11

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of BI-505 on tumor burden in patients diagnosed with smoldering multiple myeloma.

Conditions

  • Smoldering Multiple Myeloma

Interventions

DRUG

BI-505

Sponsors & Collaborators

  • BioInvent International AB

    lead INDUSTRY

Principal Investigators

  • Markus Hansson, MD, PhD · Department of Hematology,Skåne University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2014-12-31
Completion
2014-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01838369 on ClinicalTrials.gov